This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.
Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH . Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500–2504.
Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549–6555.
Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10: 558–563.
Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340–348.
Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173–1180.
Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25: 85–90.
Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706–1713.
International Prognostic Factors Study G, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906–4911.
Lewin J, Dickinson M, Voskoboynik M, Collins M, Ritchie D, Toner G . High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients. Intern Med J 2014; 44: 771–778.
Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152–1159.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
O'Kane, G., Bracken-Clarke, D., Gardiner, N. et al. A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen. Bone Marrow Transplant 51, 856–859 (2016). https://doi.org/10.1038/bmt.2015.354
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.354